基本分析
透過季節調整季營收，判斷美股整體趨勢，但注意股價有時候領先基本面的數據，應搭配其他領先指標判斷。
基本資料
個股的基本資料，以及所屬的類股和產業。
公司介紹
業務介紹
生物技術公司Seagen Inc.在美國和國際上開發和商業化治療癌症的療法。該公司提供以下產品:
ADCETRIS,一種用於治療霍奇金淋巴瘤或CD30陽性T細胞淋巴瘤患者的抗體-藥物偶聯物(ADC)。
PADCEV,一種針對Nectin-4的ADC,用於治療晚期或轉移性尿路上皮癌。
TUKYSA,一種口服小分子酪氨酸激酶抑制劑,用於治療成人晚期不可切除或轉移性HER2陽性乳腺癌。
該公司還開發了TIVDAK用於轉移性宮頸癌和其他實體瘤,Ladiratuzumab Vedotin用於轉移性乳腺癌和實體瘤,Disitamab Vedotin用於HER2靶向ADC,以及SEA-CD40、SEA-TGT、SEA-BCMA和SEA-CD70用於各種癌症疾病。
Seagen Inc.曾用名Seattle Genetics, Inc.,於2020年10月更名為Seagen Inc。該公司成立於1997年,總部位於華盛頓州的Bothell。
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
警語
1. 資料僅供參考，不做任何獲利保證及特定股票與點位推薦建議。
2. 資料並不完整，需要完整資料請至相關網站索取。
3. 任何股市數據分析皆存在倖存者偏差。
